<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01937884</url>
  </required_header>
  <id_info>
    <org_study_id>13-0374</org_study_id>
    <secondary_id>5K12HD047349-09</secondary_id>
    <nct_id>NCT01937884</nct_id>
  </id_info>
  <brief_title>Supplemental Parenteral Nutrition in Pediatric Respiratory Failure</brief_title>
  <acronym>SuPPeR</acronym>
  <official_title>Supplemental Parenteral Nutrition in Pediatric Respiratory Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Optimal delivery of nutritional support during critical illness is central to appropriate&#xD;
      intensive care unit management, and yet fundamental gaps in knowledge exist regarding timing,&#xD;
      route, dose, and type of nutritional support for critically ill infants and children.&#xD;
      Understanding how to optimize nutritional support during pediatric critical illness is&#xD;
      important because even brief periods of malnutrition in infancy result in permanent negative&#xD;
      effects on long-term neurocognitive development. Optimized nutrition support is a way to&#xD;
      improve morbidity for survivors of pediatric critical illness. Parenteral nutrition (PN)&#xD;
      supplementation could improve long-term neurocognitive outcome for pediatric critical illness&#xD;
      by preventing acute malnutrition, but has unknown effects on intestinal barrier function; a&#xD;
      proposed mechanism for late sepsis and infectious complications during critical illness.&#xD;
&#xD;
      While randomized controlled trials (RCT) support early PN in premature infants and late PN in&#xD;
      critically ill adults, the optimal time to begin PN is unknown for critically ill infants and&#xD;
      children. Acute malnutrition may develop within 48 hours of admission in critically ill&#xD;
      infants and children, and repleted energy stores are predictive of survival. And yet, due to&#xD;
      concerns for PN-associated infectious morbidity, current PICU standard of care is to&#xD;
      supplement with PN only in children who fail to enterally feed, as late as 7 days into their&#xD;
      admission. Delays in nutrition may have long-term effects on cognitive outcome in older&#xD;
      infants and children. In premature infants, PN begun within hours of birth results in&#xD;
      improved 18-month neurocognitive outcome without an increase in infectious complications. An&#xD;
      RCT is needed to determine if early PN in critically ill infants and children prevents acute&#xD;
      malnutrition and improves short and long-term outcomes of PICU hospitalization.&#xD;
&#xD;
      The central hypothesis of this proposal is that optimized early protein and calorie delivery&#xD;
      will improve nutritional outcomes and intestinal barrier function for critically ill infants&#xD;
      and children. The overall purpose of this study is to evaluate the efficacy and safety of&#xD;
      early PN as a supplement to enteral nutrition to improve nutritional delivery, nutritional&#xD;
      outcomes, and intestinal barrier function for infants and children with acute respiratory&#xD;
      failure who are mechanically ventilated in the pediatric intensive care unit.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to enroll patients&#xD;
  </why_stopped>
  <start_date type="Actual">August 2013</start_date>
  <completion_date type="Actual">August 2018</completion_date>
  <primary_completion_date type="Actual">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Prognostic Inflammatory and Nutritional Index (PINI)</measure>
    <time_frame>Change in PINI from day 0 to day 5</time_frame>
    <description>The change day 0 to day 5 of the modified Prognostic Inflammatory and Nutritional Index (PINI) is a quantitative method to monitor the relation between markers of nutrition and acute phase proteins. It allows assessment of nutrition markers in the context of acute inflammation and in response to early enteral nutrition. A higher baseline PINI score indicates higher degree of inflammation. The modified PINI is calculated by the the ratio of (C-Reactive Protein(mg/dL) x Fibrinogen (mg/dL))/ (Transferrin (mg/dL) x Transthyretin (mg/dL)). The average change in the modified PINI from day 0 to day 5 critically ill children receiving early enteral nutrition is a decrease by 5.3 +/- 3.2 (mean +/- standard error of the mean) (Briassoulis et.al. Nutrition 2001). A larger negative number for the change from day 0 to day 5 indicates a greater degree of inflammation resolution.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative Percent of Daily Goal Calories Achieved</measure>
    <time_frame>baseline and daily through day 7</time_frame>
    <description>Evaluate percentage of cumulative goal calories achieved through parenteral and enteral routes in both study arms until patient exits study participation. Measure is calculated by (sum of kcal delivered over days of study participation/number of days in study).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Intestinal Fatty Acid Binding Protein (I-FABP)</measure>
    <time_frame>baseline and day 5</time_frame>
    <description>The percent change in plasma Intestinal Fatty Acid Binding Protein from baseline to study day 5, prior to late PN initiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Citrulline</measure>
    <time_frame>baseline and day 5</time_frame>
    <description>Evaluates absolute plasma citrulline concentration as a measure of functional enterocyte mass. A higher citrulline concentration indicates a higher functional enterocyte mass. Healthy children have an average citrulline concentration of 25 +/- 9 uMol/L. Assessed on day 0 and day 5, results reported for day 0 and 5. Outcome analysis on difference between treatment groups on day 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Claudin 3</measure>
    <time_frame>baseline through hour 96</time_frame>
    <description>As a measure of enterocyte tight junctions, calculate the percent change in plasma claudin 3 concentrations from baseline (day 0) and study day 5, prior to late PN administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal Permeability</measure>
    <time_frame>day 5</time_frame>
    <description>Gastrointestinal permeability measured with the ratio of urinary recovery of lactulose and mannitol on day 5 of study participation. The range of values is generally reported as 0.02 to 2.2 with a higher value indicating greater gastrointestinal permeability. Values obtained on day 0 and day 5, day 5 reported.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With Hospital-Acquired Infections</measure>
    <time_frame>until hospital discharge or day 28 if still hospitalized</time_frame>
    <description>Record any hospital-defined hospital acquired infections through day 28 in all study participants.</description>
  </other_outcome>
  <other_outcome>
    <measure>28-day Mortality</measure>
    <time_frame>28 days</time_frame>
    <description>Death of a study patient do to any cause measured up to 28 days after study enrollment.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Acute Respiratory Failure With Hypoxia</condition>
  <condition>Malnutrition</condition>
  <arm_group>
    <arm_group_label>Early Parenteral Nutrition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive supplemental parenteral nutrition within 12 hours of enrollment. Titrated with enteral nutrition to achieve target goal calories and protein.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Late Parenteral Nutrition</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive supplemental parenteral nutrition 96 hours after enrollment. Titrated with enteral nutrition to achieve target goal calories and protein.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Parenteral Nutrition</intervention_name>
    <arm_group_label>Early Parenteral Nutrition</arm_group_label>
    <arm_group_label>Late Parenteral Nutrition</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Admitted to study hospital pediatric intensive care unit (PICU),&#xD;
&#xD;
          2. One month to 16 years of age,&#xD;
&#xD;
          3. Exhibits Acute Hypoxemic Respiratory Failure as defined as: PaO2/FiO2 ≤ 300 or&#xD;
             SpO2/FiO2 ≤ 260, No evidence of cardiac dysfunction, Mechanically ventilated,&#xD;
&#xD;
          4. Require artificial nutrition,&#xD;
&#xD;
          5. Anticipate placement of central venous line within 24 hours of admission&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Premature infants and neonates &lt; 37 weeks corrected gestational age,&#xD;
&#xD;
          2. Transfer patient on an established enteral or parenteral nutritional regimen,&#xD;
&#xD;
          3. Known allergy to lactulose or mannitol,&#xD;
&#xD;
          4. Pregnant,&#xD;
&#xD;
          5. Admit BMI &gt;30,&#xD;
&#xD;
          6. Thoracic trauma, abdominal trauma, and/or active intracranial bleeding,&#xD;
&#xD;
          7. Anuric renal failure, previous bowel surgery and/or short gut syndrome,&#xD;
&#xD;
          8. Cannot be enterally fed within 24 hours of admission according to the admitting&#xD;
             physician,&#xD;
&#xD;
          9. On extracorporeal membrane oxygenation (ECMO),&#xD;
&#xD;
         10. Expected survival &lt;24 hours or limitations to aggressive ICU care (DNR),&#xD;
&#xD;
         11. Receiving active CPR when admitted to the PICU,&#xD;
&#xD;
         12. A pre-existing bronchopleural fistula,&#xD;
&#xD;
         13. Previously enrolled and randomized into this protocol,&#xD;
&#xD;
         14. Actively enrolled in another clinical trial which at the discretion of the PI would&#xD;
             conflict with this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katri V Typpo, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona Medical Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724-5073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 1, 2013</study_first_submitted>
  <study_first_submitted_qc>September 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2013</study_first_posted>
  <results_first_submitted>January 25, 2021</results_first_submitted>
  <results_first_submitted_qc>February 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 3, 2021</results_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Arizona</investigator_affiliation>
    <investigator_full_name>Katri Typpo</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Malnutrition</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 6, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT01937884/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Early Parenteral Nutrition</title>
          <description>Patients receive supplemental parenteral nutrition within 12 hours of enrollment. Titrated with enteral nutrition to achieve target goal calories and protein over the one week study period.</description>
        </group>
        <group group_id="P2">
          <title>Late Parenteral Nutrition</title>
          <description>Patients receive supplemental parenteral nutrition 96 hours after enrollment if meeting &lt; 80% of caloric goals with enteral nutrition alone. Titrated with enteral nutrition to achieve target goal calories and protein over the one week study period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Early Parenteral Nutrition</title>
          <description>Patients receive supplemental parenteral nutrition within 12 hours of enrollment. Titrated with enteral nutrition to achieve target goal calories and protein over the one week study period.</description>
        </group>
        <group group_id="B2">
          <title>Late Parenteral Nutrition</title>
          <description>Patients receive supplemental parenteral nutrition 96 hours after enrollment if meeting &lt; 80% of caloric goals with enteral nutrition alone. Titrated with enteral nutrition to achieve target goal calories and protein over the one week study period.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.4" lower_limit="0.4" upper_limit="4.3"/>
                    <measurement group_id="B2" value="1.1" lower_limit="0.4" upper_limit="6.0"/>
                    <measurement group_id="B3" value="1.3" lower_limit="0.4" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI z score</title>
          <description>The BMI Z-Score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean. Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean. BMI Z-score cut-points of &lt; - 2.0, &gt; 1.0, &gt; 2.0, &gt; 3.0 define wasted, at risk of overweight, overweight and obese, respectively. BMI z scores were calculated used CDC growth charts for children 2 years of age and older. For children under 2 years of age the weight for age Z score is reported.</description>
          <units>Z score</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-.73" lower_limit="-1.7" upper_limit="0.2"/>
                    <measurement group_id="B2" value="-.9" lower_limit="-1.2" upper_limit="-0.03"/>
                    <measurement group_id="B3" value="-0.9" lower_limit="-1.7" upper_limit="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PELOD-2 score</title>
          <description>The Pediatric Logistic Organ Dysfunction-2 (PELOD-2) score allows assessment of the severity of organ dysfunction on a continuous scale. The score incorporates assessment of 5 organ system dysfunction (Cardiovascular, Neurologic, Respiratory, Hematologic, and Renal). Component scores for each organ system can be calculated, only the composite score which reflects baseline severity of illness and organ dysfunction is reported in our study. The minimum PELOD-2 score is 0 and the maximum is 33. A higher PELOD-2 score indicates a higher probability of death.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8" lower_limit="6" upper_limit="9"/>
                    <measurement group_id="B2" value="7" lower_limit="5" upper_limit="9"/>
                    <measurement group_id="B3" value="7.5" lower_limit="6" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Modified Prognostic Inflammatory and Nutritional Index (PINI)</title>
        <description>The change day 0 to day 5 of the modified Prognostic Inflammatory and Nutritional Index (PINI) is a quantitative method to monitor the relation between markers of nutrition and acute phase proteins. It allows assessment of nutrition markers in the context of acute inflammation and in response to early enteral nutrition. A higher baseline PINI score indicates higher degree of inflammation. The modified PINI is calculated by the the ratio of (C-Reactive Protein(mg/dL) x Fibrinogen (mg/dL))/ (Transferrin (mg/dL) x Transthyretin (mg/dL)). The average change in the modified PINI from day 0 to day 5 critically ill children receiving early enteral nutrition is a decrease by 5.3 +/- 3.2 (mean +/- standard error of the mean) (Briassoulis et.al. Nutrition 2001). A larger negative number for the change from day 0 to day 5 indicates a greater degree of inflammation resolution.</description>
        <time_frame>Change in PINI from day 0 to day 5</time_frame>
        <population>Patients with central venous access and/or arterial access removed at study day 5 did not have blood drawn for PINI measurement. All patients with paired PINI values from day 0 and day 5 obtained are analyzed based on initial group assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Parenteral Nutrition</title>
            <description>Patients receive supplemental parenteral nutrition within 12 hours of enrollment. Titrated with enteral nutrition to achieve target goal calories and protein.&#xD;
Parenteral Nutrition</description>
          </group>
          <group group_id="O2">
            <title>Late Parenteral Nutrition</title>
            <description>Patients receive supplemental parenteral nutrition 96 hours after enrollment. Titrated with enteral nutrition to achieve target goal calories and protein.&#xD;
Parenteral Nutrition</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Prognostic Inflammatory and Nutritional Index (PINI)</title>
          <description>The change day 0 to day 5 of the modified Prognostic Inflammatory and Nutritional Index (PINI) is a quantitative method to monitor the relation between markers of nutrition and acute phase proteins. It allows assessment of nutrition markers in the context of acute inflammation and in response to early enteral nutrition. A higher baseline PINI score indicates higher degree of inflammation. The modified PINI is calculated by the the ratio of (C-Reactive Protein(mg/dL) x Fibrinogen (mg/dL))/ (Transferrin (mg/dL) x Transthyretin (mg/dL)). The average change in the modified PINI from day 0 to day 5 critically ill children receiving early enteral nutrition is a decrease by 5.3 +/- 3.2 (mean +/- standard error of the mean) (Briassoulis et.al. Nutrition 2001). A larger negative number for the change from day 0 to day 5 indicates a greater degree of inflammation resolution.</description>
          <population>Patients with central venous access and/or arterial access removed at study day 5 did not have blood drawn for PINI measurement. All patients with paired PINI values from day 0 and day 5 obtained are analyzed based on initial group assignment.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="1.0"/>
                    <measurement group_id="O2" value="-3.2" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.57</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Percent of Daily Goal Calories Achieved</title>
        <description>Evaluate percentage of cumulative goal calories achieved through parenteral and enteral routes in both study arms until patient exits study participation. Measure is calculated by (sum of kcal delivered over days of study participation/number of days in study).</description>
        <time_frame>baseline and daily through day 7</time_frame>
        <population>All patients enrolled had daily nutrition data collected until end of study participation.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Parenteral Nutrition</title>
            <description>Patients receive supplemental parenteral nutrition within 12 hours of enrollment. Titrated with enteral nutrition to achieve target goal calories and protein over the one week study period.</description>
          </group>
          <group group_id="O2">
            <title>Late Parenteral Nutrition</title>
            <description>Patients receive supplemental parenteral nutrition 96 hours after enrollment if meeting &lt; 80% of caloric goals with enteral nutrition alone. Titrated with enteral nutrition to achieve target goal calories and protein over the one week study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Percent of Daily Goal Calories Achieved</title>
          <description>Evaluate percentage of cumulative goal calories achieved through parenteral and enteral routes in both study arms until patient exits study participation. Measure is calculated by (sum of kcal delivered over days of study participation/number of days in study).</description>
          <population>All patients enrolled had daily nutrition data collected until end of study participation.</population>
          <units>percent of goal kcal/day</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.8" lower_limit="98.5" upper_limit="110.2"/>
                    <measurement group_id="O2" value="103.4" lower_limit="86.4" upper_limit="110.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.68</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Intestinal Fatty Acid Binding Protein (I-FABP)</title>
        <description>The percent change in plasma Intestinal Fatty Acid Binding Protein from baseline to study day 5, prior to late PN initiation</description>
        <time_frame>baseline and day 5</time_frame>
        <population>All patients enrolled in the study with IFABP results obtained at baseline and hour 96, analyzed in initial assigned groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Parenteral Nutrition</title>
            <description>Patients receive supplemental parenteral nutrition within 12 hours of enrollment. Titrated with enteral nutrition to achieve target goal calories and protein over the one week study period.</description>
          </group>
          <group group_id="O2">
            <title>Late Parenteral Nutrition</title>
            <description>Patients receive supplemental parenteral nutrition 96 hours after enrollment if meeting &lt; 80% of caloric goals with enteral nutrition alone. Titrated with enteral nutrition to achieve target goal calories and protein over the one week study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Intestinal Fatty Acid Binding Protein (I-FABP)</title>
          <description>The percent change in plasma Intestinal Fatty Acid Binding Protein from baseline to study day 5, prior to late PN initiation</description>
          <population>All patients enrolled in the study with IFABP results obtained at baseline and hour 96, analyzed in initial assigned groups.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" lower_limit="-35.9" upper_limit="28.3"/>
                    <measurement group_id="O2" value="-25" lower_limit="-47.9" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.27</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Student's t-test on log-transformed change in IFABP.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Citrulline</title>
        <description>Evaluates absolute plasma citrulline concentration as a measure of functional enterocyte mass. A higher citrulline concentration indicates a higher functional enterocyte mass. Healthy children have an average citrulline concentration of 25 +/- 9 uMol/L. Assessed on day 0 and day 5, results reported for day 0 and 5. Outcome analysis on difference between treatment groups on day 5.</description>
        <time_frame>baseline and day 5</time_frame>
        <population>Citrulline concentrations obtained for patients with plasma samples available for analysis on study day 0 and 5</population>
        <group_list>
          <group group_id="O1">
            <title>Early Parenteral Nutrition</title>
            <description>Patients receive supplemental parenteral nutrition within 12 hours of enrollment. Titrated with enteral nutrition to achieve target goal calories and protein over the one week study period.</description>
          </group>
          <group group_id="O2">
            <title>Late Parenteral Nutrition</title>
            <description>Patients receive supplemental parenteral nutrition 96 hours after enrollment if meeting &lt; 80% of caloric goals with enteral nutrition alone. Titrated with enteral nutrition to achieve target goal calories and protein over the one week study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Citrulline</title>
          <description>Evaluates absolute plasma citrulline concentration as a measure of functional enterocyte mass. A higher citrulline concentration indicates a higher functional enterocyte mass. Healthy children have an average citrulline concentration of 25 +/- 9 uMol/L. Assessed on day 0 and day 5, results reported for day 0 and 5. Outcome analysis on difference between treatment groups on day 5.</description>
          <population>Citrulline concentrations obtained for patients with plasma samples available for analysis on study day 0 and 5</population>
          <units>umoL per Liter</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="8.6" upper_limit="14.8"/>
                    <measurement group_id="O2" value="8" lower_limit="4.7" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4" lower_limit="19" upper_limit="32.5"/>
                    <measurement group_id="O2" value="14.5" lower_limit="11.1" upper_limit="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Student's t-test on log-transformed citrulline concentration on study day 5, by treatment group</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Claudin 3</title>
        <description>As a measure of enterocyte tight junctions, calculate the percent change in plasma claudin 3 concentrations from baseline (day 0) and study day 5, prior to late PN administration.</description>
        <time_frame>baseline through hour 96</time_frame>
        <population>Included all patients with claudin 3 plasma concentrations reported at hour zero and 96, analyzed in groups as initially assigned.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Parenteral Nutrition</title>
            <description>Patients receive supplemental parenteral nutrition within 12 hours of enrollment. Titrated with enteral nutrition to achieve target goal calories and protein over the one week study period.</description>
          </group>
          <group group_id="O2">
            <title>Late Parenteral Nutrition</title>
            <description>Patients receive supplemental parenteral nutrition 96 hours after enrollment if meeting &lt; 80% of caloric goals with enteral nutrition alone. Titrated with enteral nutrition to achieve target goal calories and protein over the one week study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Claudin 3</title>
          <description>As a measure of enterocyte tight junctions, calculate the percent change in plasma claudin 3 concentrations from baseline (day 0) and study day 5, prior to late PN administration.</description>
          <population>Included all patients with claudin 3 plasma concentrations reported at hour zero and 96, analyzed in groups as initially assigned.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.8" lower_limit="11.7" upper_limit="53.6"/>
                    <measurement group_id="O2" value="111.7" lower_limit="-8.8" upper_limit="224.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.43</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Student's t-test on log-transformed percent change of claudin 3</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gastrointestinal Permeability</title>
        <description>Gastrointestinal permeability measured with the ratio of urinary recovery of lactulose and mannitol on day 5 of study participation. The range of values is generally reported as 0.02 to 2.2 with a higher value indicating greater gastrointestinal permeability. Values obtained on day 0 and day 5, day 5 reported.</description>
        <time_frame>day 5</time_frame>
        <population>Analysis of lactulose and mannitol urinary concentrations performed on all patients who received the lactulose and mannitol study test and with urinary samples obtained on day 5.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Parenteral Nutrition</title>
            <description>Patients receive supplemental parenteral nutrition within 12 hours of enrollment. Titrated with enteral nutrition to achieve target goal calories and protein over the one week study period.</description>
          </group>
          <group group_id="O2">
            <title>Late Parenteral Nutrition</title>
            <description>Patients receive supplemental parenteral nutrition 96 hours after enrollment if meeting &lt; 80% of caloric goals with enteral nutrition alone. Titrated with enteral nutrition to achieve target goal calories and protein over the one week study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Gastrointestinal Permeability</title>
          <description>Gastrointestinal permeability measured with the ratio of urinary recovery of lactulose and mannitol on day 5 of study participation. The range of values is generally reported as 0.02 to 2.2 with a higher value indicating greater gastrointestinal permeability. Values obtained on day 0 and day 5, day 5 reported.</description>
          <population>Analysis of lactulose and mannitol urinary concentrations performed on all patients who received the lactulose and mannitol study test and with urinary samples obtained on day 5.</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" lower_limit="0.13" upper_limit="0.78"/>
                    <measurement group_id="O2" value="0.17" lower_limit="0.13" upper_limit="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.88</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Hospital-Acquired Infections</title>
        <description>Record any hospital-defined hospital acquired infections through day 28 in all study participants.</description>
        <time_frame>until hospital discharge or day 28 if still hospitalized</time_frame>
        <population>All study participants</population>
        <group_list>
          <group group_id="O1">
            <title>Early Parenteral Nutrition</title>
            <description>Patients receive supplemental parenteral nutrition within 12 hours of enrollment. Titrated with enteral nutrition to achieve target goal calories and protein over the one week study period.</description>
          </group>
          <group group_id="O2">
            <title>Late Parenteral Nutrition</title>
            <description>Patients receive supplemental parenteral nutrition 96 hours after enrollment if meeting &lt; 80% of caloric goals with enteral nutrition alone. Titrated with enteral nutrition to achieve target goal calories and protein over the one week study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hospital-Acquired Infections</title>
          <description>Record any hospital-defined hospital acquired infections through day 28 in all study participants.</description>
          <population>All study participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.43</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>28-day Mortality</title>
        <description>Death of a study patient do to any cause measured up to 28 days after study enrollment.</description>
        <time_frame>28 days</time_frame>
        <population>Determined for all study participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Parenteral Nutrition</title>
            <description>Patients receive supplemental parenteral nutrition within 12 hours of enrollment. Titrated with enteral nutrition to achieve target goal calories and protein over the one week study period.</description>
          </group>
          <group group_id="O2">
            <title>Late Parenteral Nutrition</title>
            <description>Patients receive supplemental parenteral nutrition 96 hours after enrollment if meeting &lt; 80% of caloric goals with enteral nutrition alone. Titrated with enteral nutrition to achieve target goal calories and protein over the one week study period.</description>
          </group>
        </group_list>
        <measure>
          <title>28-day Mortality</title>
          <description>Death of a study patient do to any cause measured up to 28 days after study enrollment.</description>
          <population>Determined for all study participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected over 14 days, from time of patient enrollment</time_frame>
      <desc>Adverse event reporting follows the clinicaltrials.gov definitions and includes all-cause mortality, serious adverse events, and other adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Early Parenteral Nutrition</title>
          <description>Patients receive supplemental parenteral nutrition within 12 hours of enrollment. Titrated with enteral nutrition to achieve target goal calories and protein over the one week study period.</description>
        </group>
        <group group_id="E2">
          <title>Late Parenteral Nutrition</title>
          <description>Patients receive supplemental parenteral nutrition 96 hours after enrollment if meeting &lt; 80% of caloric goals with enteral nutrition alone. Titrated with enteral nutrition to achieve target goal calories and protein over the one week study period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <description>Identification of a deep vein thrombosis by ultrasound imaging</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration of gastric contents</sub_title>
                <description>Aspiration event as determined by the Clinical team</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hospital-Acquired infection</sub_title>
                <description>Hospital-determined hospital acquired infections</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <description>Glucose value &gt;200 mg/dL</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Desaturation &lt; 85%</sub_title>
                <description>Desaturation event with SaO2 &lt; 85%</description>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was discontinued early due to slow enrollment. The small study size limits interpretation of clinical and biochemical outcomes data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Katri Typpo</name_or_title>
      <organization>University of Arizona</organization>
      <phone>5206265485</phone>
      <email>ktyppo@email.arizona.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

